blinatumomab

a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma

Also Known As:

Networked: 515 relevant articles (104 outcomes, 86 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Zugmaier, Gerhard: 41 articles (01/2022 - 08/2008)
2.	Topp, Max S: 28 articles (01/2021 - 06/2011)
3.	Gökbuget, Nicola: 20 articles (01/2021 - 06/2011)
4.	Bargou, Ralf C: 17 articles (01/2021 - 03/2009)
5.	Stein, Anthony S: 16 articles (11/2022 - 01/2016)
6.	Locatelli, Franco: 16 articles (01/2022 - 12/2016)
7.	Brüggemann, Monika: 16 articles (11/2021 - 06/2011)
8.	Nagorsen, Dirk: 16 articles (10/2019 - 06/2009)
9.	Kantarjian, Hagop M: 15 articles (09/2022 - 03/2014)
10.	Aldoss, Ibrahim: 14 articles (11/2022 - 01/2016)

Related Diseases

1.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 02/01/2022 - "The CD19-targeting bispecific T-cell engager blinatumomab has shown remarkable efficacy in patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. " 03/01/2022 - "Blinatumomab, a bispecific CD3/CD19 antibody, is approved for relapsed/refractory acute lymphoblastic leukemia (ALL) and has proven its efficacy with good complete response (CR) rates and molecular responses in several trials. " 03/17/2022 - "Among them, the US Food and Drug Administration (FDA)-approved blinatumomab (BLI) is very effective in eliminating the minimum residual disease (MRD) of acute lymphoblastic leukemia (ALL), resulting in long-term remission in many individuals. " 01/01/2022 - "Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that has proven efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). " 01/01/2019 - "In the data reported herein, we present an interesting case of a 42-year-old patient with primary refractory B-cell acute lymphoblastic leukemia who achieved complete morphologic remission after one cycle of blinatumomab as a single agent. "
2.	Residual Neoplasm 10/01/2015 - "In the phase II trial that served as the basis for approval, blinatumomab demonstrated significant single-agent activity and induced remission [complete remission (CR) and CR with incomplete recovery of peripheral blood counts (CRh)] in 43% of 189 adult patients with RR-ALL; the majority of responders (82%) also attained negative minimal residual disease (MRD(-)) status that did not generally translate into long-term remissions in most cases. " 06/08/2021 - "Two randomized controlled trials have very recently demonstrated an improved reduction in minimal residual disease as well as an increased survival for patients treated with blinatumomab compared to standard consolidation treatment in first relapse. " 01/17/2022 - "Two patients were administered blinatumomab for refractory relapse without complete remission (CR), one due to primary refractory disease, and ten patients were in CR with minimal residual disease (MRD) ≥ 10-3. The response rate in our cohort of patients was 85%, with subsequent feasible HSCT in 11 out of 13 children. " 11/27/2020 - "In addition, approximately 80% of patients getting complete remission with evidence of minimal residual disease (MRD) achieved a complete MRD response with the use of blinatumomab. " 03/01/2019 - "The efficiency of blinatumomab was assessed in terms of complete remission, minimal residual disease, overall survival, and tolerability of treatment. "
3.	Philadelphia Chromosome 04/01/2016 - "Blinatumomab (Blincyto®) is a newly approved option for inducing remission in individuals with relapsed or refractory Philadelphia chromosome-negative B-cell ALL. " 12/01/2022 - "Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial." 12/01/2022 - "This multicenter open-label single-arm China registrational study evaluated the safety, efficacy, and pharmacokinetics of blinatumomab in Chinese adults with Philadelphia chromosome-negative (Ph-) R/R BCP-ALL (NCT03476239). " 01/01/2021 - "Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study." 01/01/2020 - "Bayesian data augmentation was applied to improve power to 80% with data from a phase 3 blinatumomab study in r/r Philadelphia chromosome-negative ALL. "
4.	Neoplasms (Cancer) 05/19/2022 - "Since the first approval of blinatumomab by the United States Food and Drug Administration (US FDA), various bsAb-based ICEs have been developed for the effective treatment of patients with cancer. " 01/01/2021 - "Since the landmark FDA approval at the end of 2014 of the anti-CD3 × anti-CD19 bispecific antibody blinatumomab (Blincyto®) for the treatment of relapsed/refractory B-cell acute lymphoblastic leukaemia, ~100 clinical trials investigating the safety and efficacy of CD3+ bispecific T-cell redirectors for cancer have been initiated. " 08/15/2008 - "Blinatumomab also led to clearance of tumor cells from bone marrow and liver. " 01/01/2022 - "In vivo study showed that OVV-CD19BiTE selectively replicated within tumor tissue, and contributed to a more significantly increased percentage of CD3, CD8, and naïve CD8 T subpopulations within tumors in contrast to blinatumomab. " 11/01/2021 - "In this study, we investigated whether the adoptive transfer of ex vivo expanded γ9δ2 T cells could act as the effector of blinatumomab to enhance blinatumomab's antitumor activity against B-cell malignancies in vivo. "
5.	Leukemia 01/01/2022 - "Blinatumomab and CAR T-cell therapy showed excellent remission rates and manageable toxicity in pediatric patients with relapsed/refractory leukemia. " 01/01/2023 - "Furthermore, this is the first report on the efficacy of blinatumomab in treating CNS leukemia with both of the cerebral spinal fluid and the cerebral parenchymal involvement. " 11/27/2023 - "This study describes current institutional practices surrounding administration of 28-day blinatumomab infusions in children with leukemia and offers a starting point for institutional benchmarking and standardization of practice." 01/01/2022 - "Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study." 06/01/2023 - "Treatment of Relapsed B/T-cell Mixed Phenotype Acute Leukemia With Blinatumomab."

Related Drugs and Biologics

1.	blinatumomab
2.	Chimeric Antigen Receptors
3.	Inotuzumab Ozogamicin
4.	Monoclonal Antibodies
5.	ponatinib
6.	tisagenlecleucel
7.	Antigens
8.	Tyrosine Kinase Inhibitors
9.	Single-Chain Antibodies
10.	Bispecific Antibodies

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Immunotherapy
4.	Hematopoietic Stem Cell Transplantation
5.	Cell Transplantation